Printer Friendly

DEPRENYL RESEARCH LIMITED ANNOUNCES FOURTH QUARTER RESULTS TO BE RELEASED MID-FEBRUARY

 TORONTO, Feb. 2 /PRNewswire/ -- Deprenyl Research Limited (NASDAQ: DEPLF; Toronto) today announced that its fourth quarter results, expected to be approved at the board meeting scheduled for February 11, will continue to show growth in revenues from Eldepryl(R). These results will be released following their approval by the board.
 The company's pattern of increased investment in the launch of new products and the expansion of its pipeline of pharmaceuticals, particularly in its dermatologic line, remains on track. The second edition of its publication "Pipeline Progress" is scheduled for release in mid-February and will show an increase in the number of products in its pipeline, particularly its dermatologic products, scheduled for launch within the next two years.
 Deprenyl Research Limited is a Canadian Pharmaceutical Company with several development stage affiliates. It develops and markets pharmaceutical agents for neurologic diseases, chronic diseases and diseases of aging and dermatology.
 -0- 2/2/93
 /CONTACT: Edward L. Foster, CA, vice president and CFO, or (investors) Deborah Worobec of Deprenyl Research Limited, 416-537-4372, or (fax) 416-537-1653, or Jim Tolan, senior vice president, or Nicholas Biro, Principal of O'Connor Biro & Associates, 708-498-2284, or (fax) 708-498-3144, for Deprenyl Research Limited/
 (DEPLF)


CO: Deprenyl Research Limited ST: Ontario IN: MTC SU:

TS -- NY075 -- 1938 02/02/93 13:43 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 2, 1993
Words:213
Previous Article:STERLING SOFTWARE ANNOUNCES REDEMPTION OF 8 PERCENT CONVERTIBLE SENIOR SUBORDINATED DEBENTURES DUE 2001
Next Article:PSI ENERGY $200 MILLION CUMULATIVE PREFERRED STOCK (SHELF) RATED 'BBB'
Topics:


Related Articles
DEPRENYL RESEARCH LIMITED REPORTS EARNINGS
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL ANNOUNCES AGREEMENT TO ACQUIRE CONTROL OF LIPOPHARM
DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDING JUNE 30, 1992
DEPRENYL RESEARCH LIMITED REASSURES SHAREHOLDERS
DEPRENYL USA, INC. REPORTS RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPT. 30, 1992; EXPECTS TO FILE ITS FIRST INVESTIGATIONAL NEW DRUG
DEPRENYL USA REPORTS YEAR END 1992 RESULTS; CONFIRMS ALA PHOTODYNAMIC DEVELOPMENT ON SCHEDULE; PROPOSES NAME CHANGE TO DUSA PHARMACEUTICALS
DEPRENYL RESEARCH REPORTS EARNINGS
DEPRENYL USA REPORTS FIRST QUARTER RESULTS ON PLAN INITIAL CLINICAL TRIALS PROCEEDING ON SCHEDULE
MGI PHARMA TAKES ONE TIME CHARGE IN 1993 FOURTH QUARTER

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters